市場調査レポート

商品コード

1464750

先天性高インスリン血症治療薬市場：適応症タイプ、治療法、投与経路、流通チャネル、エンドユーザー別- 世界予測2024-2030年

Congenital Hyperinsulinism Treatment Market by Indication Type, Treatment, Route of Administration, Distribution Channel, End-Users - Global Forecast 2024-2030

出版日: 2024年04月17日 | 発行: 360iResearch

| ページ情報: 英文 192 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF, Excel & Online Access - 1 Year (Single User License)

USD 4,749 746,257円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Up to 5 User License)

USD 5,749 903,397円

レポートPDF及びExcelを5名まで共有ご利用頂けるライセンスです。ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Site License)

USD 6,749 1,060,537円

レポートPDF及びExcelを同一事業所（所在地）内のすべての方でご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Enterprise User License)

USD 8,749 1,374,817円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

先天性高インスリン血症治療薬市場規模は2023年に1億8,253万米ドルと推計され、2024年には1億9,220万米ドルに達し、CAGR 5.61％で2030年には2億6,764万米ドルに達すると予測されます。

先天性高インスリン血症（CHI）は、乳幼児や小児における過剰なインスリン分泌を特徴とする複雑な病態であり、重篤な低血糖を引き起こします。CHIの治療選択肢は多面的であり、血糖値を正常範囲内に維持し、低血糖エピソードを予防することを目的としています。これらには、ジアゾキシド、オクトレオチド、ランレオチドのような新薬などの内科的治療や、重症例では外科的介入が含まれます。CHI治療の選択肢を広げた主な要因としては、診断手法の進歩、疾患の遺伝的・分子的基盤の理解向上、インスリン分泌に関与する特定の経路を標的とした新規の薬理学的薬剤の開発などが挙げられます。しかし、CHIの治療には、ジアゾキシドによる体液貯留やオクトレオチドによる胃腸症状などの副作用の可能性や、症状の緩和が不完全であったり低血糖が再発したりするリスクなどの課題があります。これらの課題に対処するためには、より的を絞った低侵襲の治療戦略、遺伝子プロファイリングに基づく個別化医療、より効果的で安全な薬剤の開発などの研究を継続する必要があります。インスリンの産生と分泌をリアルタイムで調節できる人工膵臓システムの登場は、CHIを管理するための画期的なアプローチを提供し、CHIに対する先進的な治療を提供します。

主な市場の統計
基準年[2023］	1億8,253万米ドル
予測年［2024]	1億9,220万米ドル
予測年 [2030]	2億6,764万米ドル
CAGR（%）	5.61%

適応症の種類非定型CHI治療における個別化アプローチの必要性

非定型先天性高インスリン血症は、一般的でない遺伝子変異を有するCHI患者のサブセットであり、その症状や重症度は様々です。この病型では、多くの場合、薬物療法とモニタリング戦略を組み合わせた柔軟な治療アプローチが必要です。びまん性先天性インスリン分泌過多症は、膵臓全体のインスリン細胞が異常な挙動を示すことを特徴とし、全身的な治療アプローチが必要となります。細胞病変が広範囲に及ぶため、手術は最後の手段であり、ジアゾキシドやオクトレオチドを含む薬物療法が主要な治療法です。局所性先天性高インスリン血症は、膵臓内の異常細胞の限局した領域が特徴です。治療戦略としては、患部の外科的切除が望ましく、治癒の可能性があります。画像診断と手術手技の進歩により、局所性CHIの治療成績は大きく向上しています。

エンドユーザー病院における先天性高インスリン血症に対する多様な治療の必要性

外来手術センター（ASC）は、軽度の外科的介入や外来処置が必要な先天性インスリン分泌過多症の重症度の低い症例に好まれています。ASCは効率的で、低コストで、退院までの時間が短いため、患者や介護者にとって魅力的です。ASCは高度な医療技術を備えるようになってきており、従来は病院でしか受けられなかった様々なサービスを提供できるようになってきています。病院は先天性高インスリン血症の重症例、特に複雑な外科的介入や集中治療を必要とする症例を管理するための主要な選択肢です。病院は、診断、手術、術後管理を含む包括的なケアを一つ屋根の下で提供します。病院は幅広い設備と専門医を備えており、より複雑な先天性インスリン分泌過多症の症例に対応するのに適しています。専門クリニックは、先天性インスリン分泌過多症の管理、特に継続的な管理と介入後のフォローアップにおいて、専門的な治療を行うために選択されます。このようなクリニックでは、高いレベルの専門知識と個別化されたケアプランが提供されることが多いです。

地域別の洞察

南北アメリカでは、先天性インスリン分泌過多症市場は堅調であり、特に米国における研究開発への強い注力により、先進的な治療法の採用率が高く、大手製薬企業が積極的に参入しています。同地域の企業は、先進的な先天性高インスリン血症治療薬の導入を支援するため、さまざまな研究開発（R&D）活動に投資しています。APACのシナリオは、特に中国やヘルスケアなどの国々において、意識の高まりと医療インフラの改善に後押しされた急成長によって特徴づけられます。中東・アフリカは、医療へのアクセスと質のばらつきに悩まされています。欧州企業がこの市場で大きな存在感を示しているのは、この地域が革新的な治療法や国際共同研究に対してオープンであることを示しています。研究活動に対する政府の支援により、この地域では病院や専門クリニックにおける調査活動の拡大が見られます。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは先天性高インスリン血症治療薬市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、先天性高インスリン血症治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.先天性高インスリン血症治療薬市場の市場規模および予測は？

2.先天性高インスリン血症治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.先天性高インスリン血症治療薬市場の技術動向と規制枠組みは？

4.先天性高インスリン血症治療薬市場における主要ベンダーの市場シェアは？

5.先天性高インスリン血症治療薬市場への参入に適した形態や戦略的手段は？

市場力学
- 促進要因
  - 先天性高インスリン血症の罹患率の増加
  - 先天性高インスリン症の診断を促進する政府の取り組み
- 抑制要因
  - 先天性高インスリン症に対する限定的な償還が利用可能
- 機会
  - 先天性高インスリン血症の治療の進歩に向けた継続的な研究開発
  - 先天性高インスリン血症治療薬の承認が進む
- 課題
  - 診断上の課題と治療の合併症の可能性
市場セグメンテーション分析
- 適応症タイプ：非典型CHIの治療にはより個別化されたアプローチが必要
- エンドユーザー：病院における先天性高インスリン血症に対する多様な治療法の必要性
市場ディスラプション分析
ポーターのファイブフォース分析
バリューチェーンとクリティカルパス分析
価格分析
技術分析
特許分析
貿易分析
規制枠組みの分析

第6章先天性高インスリン血症治療薬市場適応症の種類別

非典型先天性高インスリン血症
びまん性先天性高インスリン血症
局所性先天性高インスリン血症

第7章先天性高インスリン血症治療薬市場治療別

食事管理
薬物
外科的介入

第8章先天性高インスリン血症治療薬市場：投与経路別

オーラル
非経口

第9章先天性高インスリン血症治療薬市場：流通チャネル別

病院薬局
オンライン薬局
小売薬局

第10章先天性高インスリン血症治療薬市場：エンドユーザー別

外来手術センター
病院
専門クリニック

第11章南北アメリカの先天性高インスリン血症治療薬市場

アルゼンチン
ブラジル
カナダ
メキシコ
米国

第12章アジア太平洋地域の先天性高インスリン血症治療薬市場

オーストラリア
中国
インド
インドネシア
日本
マレーシア
フィリピン
シンガポール
韓国
台湾
タイ
ベトナム

第13章欧州・中東・アフリカの先天性高インスリン血症治療薬市場

デンマーク
エジプト
フィンランド
フランス
ドイツ
イスラエル
イタリア
オランダ
ナイジェリア
ノルウェー
ポーランド
カタール
ロシア
サウジアラビア
南アフリカ
スペイン
スウェーデン
スイス
トルコ
アラブ首長国連邦
英国

第14章競合情勢

市場シェア分析2023
FPNVポジショニングマトリックス, 2023
競合シナリオ分析
- C-Pathと先天性高インスリン症インターナショナルがデータ共有契約を発表
- ジーランド・ファーマ、先天性高インスリン血症治療薬ダシグルカゴンの新薬申請を米国FDAに提出
- リズム・ファーマシューティカルズ、Xinvento B.V.と治験薬ポートフォリオの買収を発表
戦略分析と提言

第15章競争力のあるポートフォリオ

主要企業プロファイル
主要製品ポートフォリオ

図表

LIST OF FIGURES

FIGURE 1. CONGENITAL HYPERINSULINISM TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CONGENITAL HYPERINSULINISM TREATMENT MARKET DYNAMICS
FIGURE 7. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 10. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 16. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. CONGENITAL HYPERINSULINISM TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 26. CONGENITAL HYPERINSULINISM TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

TABLE 1. CONGENITAL HYPERINSULINISM TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ATYPICAL CONGENITAL HYPERINSULINISM, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ATYPICAL CONGENITAL HYPERINSULINISM, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIFFUSE CONGENITAL HYPERINSULINISM, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIFFUSE CONGENITAL HYPERINSULINISM, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY FOCAL CONGENITAL HYPERINSULINISM, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY FOCAL CONGENITAL HYPERINSULINISM, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIAZOXIDE, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIAZOXIDE, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY GLUCAGON, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY NIFEDIPINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY NIFEDIPINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY OCTREOTIDE, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 53. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 54. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 55. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 56. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 57. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 58. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 59. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 60. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 61. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 62. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 63. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 64. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 65. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 66. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 67. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 68. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 69. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 70. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 71. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 72. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 73. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 74. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 75. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 76. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 77. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 78. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 79. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 80. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 81. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 82. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 83. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 84. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 85. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 86. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 87. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 88. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 89. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 90. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 91. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 92. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 93. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 94. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 95. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 96. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 97. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 98. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 99. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 100. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 101. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 102. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 103. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 104. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 105. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 106. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 107. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 108. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 109. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 110. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 111. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 112. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 113. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 114. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 115. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 116. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 117. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 118. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 119. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 120. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 121. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 122. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 123. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 124. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 125. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 126. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 127. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 128. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 129. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 130. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 132. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 134. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 136. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 138. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 140. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 142. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 144. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 145. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 146. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 147. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 148. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 149. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 150. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 151. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 152. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 153. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 154. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 155. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 156. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 157. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 158. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 159. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 160. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 161. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 162. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 163. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 164. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 165. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 166. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 167. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 168. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 169. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 170. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 171. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 172. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 173. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 174. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 175. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 176. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 177. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 178. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 179. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 180. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 181. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 182. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 183. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 184. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 185. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 186. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 187. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 188. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 189. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 190. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 191. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 192. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 193. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 194. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 195. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 196. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 197. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 198. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 199. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 200. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 201. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 202. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 203. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 204. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 205. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 206. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 207. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 208. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 209. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 210. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 211. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 212. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 213. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 214. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 215. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 216. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 217. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 218. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 219. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 220. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 221. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 222. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 223. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 224. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 225. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 226. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 227. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 228. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 229. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 230. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 231. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 232. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 233. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 234. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 235. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 236. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 237. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 238. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 239. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 240. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 241. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 242. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 243. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 244. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 245. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 246. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 247. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 248. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 249. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 250. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 251. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 252. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 253. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 254. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 255. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 256. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 257. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 258. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 259. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 260. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 261. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 262. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 263. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 264. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 265. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 266. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 267. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 268. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 269. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 270. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 271. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 272. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 273. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 274. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 275. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 276. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 277. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 278. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 279. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 280. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 281. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 282. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 283. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 284. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 285. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 286. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 287. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 288. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET S

Product Code: MRR-F97DD5A7D994

[192 Pages Report] The Congenital Hyperinsulinism Treatment Market size was estimated at USD 182.53 million in 2023 and expected to reach USD 192.20 million in 2024, at a CAGR 5.61% to reach USD 267.64 million by 2030.

Congenital hyperinsulinism (CHI) is a complex condition characterized by excessive insulin production in infants and children, leading to severe hypoglycemia. CHI treatment options are multifaceted, aiming to maintain blood glucose levels within a normal range and prevent hypoglycemic episodes. These include medical therapies such as diazoxide, octreotide, and newer drugs like lanreotide, as well as surgical interventions in more severe cases. The major factors contributing to the expansion of CHI treatment options include advancements in diagnostic methodologies, improved understanding of the genetic and molecular bases of the disease, and the development of novel pharmacological agents targeting specific pathways involved in insulin secretion. However, treatments for CHI come with challenges, including potential side effects, such as fluid retention with diazoxide or gastrointestinal symptoms with octreotide, and the risk of incomplete relief from symptoms or hypoglycemia recurrence. Addressing these challenges involves ongoing research into more targeted and less invasive therapeutic strategies, personalized medicine based on genetic profiling, and developing more effective and safer drugs. The advent of artificial pancreas systems that could regulate insulin production and release in real-time offers a transformative approach to managing CHI, providing advanced treatment for the condition.

KEY MARKET STATISTICS
Base Year [2023]	USD 182.53 million
Estimated Year [2024]	USD 192.20 million
Forecast Year [2030]	USD 267.64 million
CAGR (%)	5.61%

Indication Type: Need for a more personalized approach to treat Atypical CHI

Atypical congenital hyperinsulinism represents a subset of CHI patients with less common genetic mutations, leading to variable presentation and severity. This form requires flexible, tailored treatment approaches, often involving a combination of medical therapy and monitoring strategies. Diffuse Congenital hyperinsulinism is characterized by insulin cells across the pancreas behaving abnormally, necessitating a systemic treatment approach. Surgery can be a last resort due to the pervasive nature of cell involvement, and medication management, including diazoxide and octreotide, remains the primary treatment. Focal congenital hyperinsulinism is marked by a localized region of abnormal cells within the pancreas. The preferred treatment strategy is surgical removal of the affected area, offering a potential cure. Advances in imaging and surgical techniques have greatly enhanced the treatment outcomes for focal CHI.

End-Users: Need for a diverse range of treatments for congenital hyperinsulinism in hospitals

Ambulatory surgery centers (ASCs) are preferred for less severe cases of congenital hyperinsulinism that necessitate minor surgical interventions or outpatient procedures. The efficiency, lower cost, and faster discharge times make ASCs attractive for patients and caregivers. ASCs are increasingly equipped with advanced medical technologies that enable them to offer a range of services that were traditionally available only in hospital settings. Hospitals are the primary choice for managing severe cases of congenital hyperinsulinism, especially those requiring complex surgical interventions or intensive care. They offer comprehensive care, including diagnostics, surgery, and post-operative management, under one roof. Hospitals are equipped with a broad range of facilities and specialists, making them well-suited for handling congenital hyperinsulinism cases with higher levels of complexity. Specialty clinics are chosen for their specialized care in managing congenital hyperinsulinism, particularly for ongoing management and follow-up post-intervention. These clinics often provide a high level of expertise and personalized care plans.

Regional Insights

In the Americas, the congenital hyperinsulinism market is robust, with a high adoption rate of advanced treatments and active participation from leading pharmaceuticals, driven by a strong focus on research and development, particularly in the United States. Companies in the region have invested in various research & development (R&D) activities to support the introduction of advanced congenital hyperinsulinism treatment. The APAC scenario is marked by rapid growth fueled by increasing awareness and improving healthcare infrastructure, especially in countries such as China and India. EMEA presents a mixed environment with strong healthcare systems in Europe facilitating access to treatments and encouraging clinical trials, while the Middle East and Africa grapple with variability in healthcare access and quality. European companies have a significant presence in the market, indicative of the region's openness to innovative treatments and international collaborations. With government support for research activities, the region is witnessing an expansion of congenital hyperinsulinism treatment activities in hospitals & specialty clinics.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Congenital Hyperinsulinism Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Congenital Hyperinsulinism Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Congenital Hyperinsulinism Treatment Market, highlighting leading vendors and their innovative profiles. These include Crinetics Pharmaceuticals, Inc., Eiger Biopharmaceuticals Inc., Hanmi Pharmaceutical Company, Hua Medicine (Shanghai) Co., Ltd., Novartis AG, Rezolute, Inc., Rhythm Pharmaceuticals, Inc., Twist Bioscience Corporation, Xeris Biopharma Holdings, Inc., XOMA Corporation, and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Congenital Hyperinsulinism Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Indication Type
- Atypical Congenital Hyperinsulinism
- Diffuse Congenital Hyperinsulinism
- Focal Congenital Hyperinsulinism

Treatment
- Dietary Management
- Drugs
  - Diazoxide
  - Glucagon
  - Nifedipine
  - Octreotide

Surgical Intervention

Route of Administration
- Oral
- Parenteral

Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

End-Users
- Ambulatory Surgery Centers
- Hospitals
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Congenital Hyperinsulinism Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Congenital Hyperinsulinism Treatment Market?

3. What are the technology trends and regulatory frameworks in the Congenital Hyperinsulinism Treatment Market?

4. What is the market share of the leading vendors in the Congenital Hyperinsulinism Treatment Market?

5. Which modes and strategic moves are suitable for entering the Congenital Hyperinsulinism Treatment Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increase in prevalence of congenital hyperinsulinism disease
  - 5.1.1.2. Government initiatives promoting congenital hyperinsulinism diagnosis
- 5.1.2. Restraints
  - 5.1.2.1. Limited reimbursement available for congenital hyperinsulinism
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing R&D for advancing treatment of congenital hyperinsulinism
  - 5.1.3.2. Emerging approval of congenital hyperinsulinism treatments
- 5.1.4. Challenges
  - 5.1.4.1. Diagnostic challenges and possible complications of the treatment
5.2. Market Segmentation Analysis
- 5.2.1. Indication Type: Need for a more personalized approach to treat Atypical CHI
- 5.2.2. End-Users: Need for a diverse range of treatments for congenital hyperinsulinism in hospitals
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Congenital Hyperinsulinism Treatment Market, by Indication Type

6.1. Introduction
6.2. Atypical Congenital Hyperinsulinism
6.3. Diffuse Congenital Hyperinsulinism
6.4. Focal Congenital Hyperinsulinism

7. Congenital Hyperinsulinism Treatment Market, by Treatment

7.1. Introduction
7.2. Dietary Management
7.3. Drugs
7.4. Surgical Intervention

8. Congenital Hyperinsulinism Treatment Market, by Route of Administration

8.1. Introduction
8.2. Oral
8.3. Parenteral

9. Congenital Hyperinsulinism Treatment Market, by Distribution Channel

9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies

10. Congenital Hyperinsulinism Treatment Market, by End-Users

10.1. Introduction
10.2. Ambulatory Surgery Centers
10.3. Hospitals
10.4. Specialty Clinics

11. Americas Congenital Hyperinsulinism Treatment Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Congenital Hyperinsulinism Treatment Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Congenital Hyperinsulinism Treatment Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. C-Path and Congenital Hyperinsulinism International Announce Data Sharing Agreement
- 14.3.2. Zealand Pharma Submits New Drug Application to US FDA for Dasiglucagon In Congenital Hyperinsulinism
- 14.3.3. Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio

先天性高インスリン血症治療薬市場：適応症タイプ、治療法、投与経路、流通チャネル、エンドユーザー別- 世界予測2024-2030年

Congenital Hyperinsulinism Treatment Market by Indication Type, Treatment, Route of Administration, Distribution Channel, End-Users - Global Forecast 2024-2030

本レポートは、以下の側面に関する貴重な洞察を提供しています：

本レポートは、以下のような主要な質問に対応しています：

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

第6章 先天性高インスリン血症治療薬市場適応症の種類別

第7章 先天性高インスリン血症治療薬市場治療別

第8章 先天性高インスリン血症治療薬市場：投与経路別

第9章 先天性高インスリン血症治療薬市場：流通チャネル別

第10章 先天性高インスリン血症治療薬市場：エンドユーザー別

第11章 南北アメリカの先天性高インスリン血症治療薬市場

第12章 アジア太平洋地域の先天性高インスリン血症治療薬市場

第13章 欧州・中東・アフリカの先天性高インスリン血症治療薬市場

第14章 競合情勢

第15章 競争力のあるポートフォリオ